{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T14:36:16Z","timestamp":1777905376181,"version":"3.51.4"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Systemic lupus erythematosus (SLE) overlapping with Sj\u00f6gren\u2019s disease (SjD) or not may progress differently in the clinical course. We aimed to explore the impact of SjD on lupus low disease activity state (LLDAS) or remission achievement in a real-world cohort.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The medical records of patients in the Peking University First Hospital SLE (PKUFHS) cohort from 2007 to 2019 were retrospectively reviewed. Demographics, SLE and SjD features, treatment, and whether in LLDAS\/remission on treatment (RONT) or not at each visit were collected. According to overlapped SjD and its immunological features, all patients were categorized into the following subgroups: SjD with anti-SSA single positivity, SjD with anti-SSA\/SSB double positivity, SjD with baseline hypergammaglobulinemia, and those without SjD. The Cox proportional hazards model in propensity score-matched cohorts was used to estimate the impact of different SjD characteristics on LLDAS\/RONT and each component after correcting for known confounders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 9,415 visits originating from 626 SLE patients were included. Overlapping SjD was identified in 77 (12.3%) patients. Patients with SLE overlapping SjD were significantly older at onset and predominantly female with more frequent hematological involvement. Overlapping SjD and anti-SSA\/SSB double-positive SjD were associated with 29%\u201338% and 50%\u201353% reduction, respectively, in RONT achievement in SLE patients. Both overlapping SjD and SjD with baseline hypergammaglobulinemia acted as protectors for LLDAS achievement with 24% and 31% increments, respectively, and anti-SSA single-positive SjD showed no definite effect. The most affected target component was normal serology, with hazard ratios of 0.64\u20130.85 for overlapping SjD and anti-SSA\/SSB double-positive SjD, and 1.15\u20131.24 for SjD with baseline hypergammaglobulinemia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Overlapping SjD facilitated reaching LLDAS yet hampered further RONT, anti-SSA\/SSB double-positive SjD acted as a hazardous factor, SjD with baseline hypergammaglobulinemia acted as a protective factor, and anti-SSA single-positive SjD acted as an irrelevant factor for RONT achievement.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1639252","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:25:11Z","timestamp":1759123511000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of Sj\u00f6gren\u2019s disease and its immunological characteristics on reaching remission or low disease activity state in systemic lupus erythematosus patients: a propensity score-matched longitudinal study"],"prefix":"10.3389","volume":"16","author":[{"given":"Haoze","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanlan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanjie","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuoli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa120","article-title":"Frequencies and predictors of the Lupus Low Disease Activity State and remission in treatment-na\u00efve patients with systemic lupus erythematosus","volume":"59","author":"Gao","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s13075-016-1163-2","article-title":"Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort","volume":"18","author":"Golder","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090804","article-title":"Secondary Sjogren's syndrome in systemic lupus erythematosus defines a distinct disease subset","volume":"37","author":"Baer","year":"2010","journal-title":"J Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-007-0720-0","article-title":"Clinical and laboratory profiles of systemic lupus erythematosus associated with Sj\u00f6gren syndrome in China: a study of 542 patients","volume":"27","author":"Pan","year":"2008","journal-title":"Clin Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/art.20093","article-title":"Sj\u00f6gren's syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sj\u00f6gren's syndrome","volume":"50","author":"Manoussakis","year":"2004","journal-title":"Arthritis Rheum"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190250","article-title":"Sj\u00f6gren syndrome in systemic lupus erythematosus: A subset characterized by a systemic inflammatory state","volume":"47","author":"Ruacho","year":"2020","journal-title":"J Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209489","article-title":"Remission in systemic lupus erythematosus: durable remission is rare","volume":"76","author":"Wilhelm","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180433","article-title":"Predictors of remission and low disease activity state in systemic lupus erythematosus: data from a multiethnic, multinational latin american cohort","volume":"46","author":"Ugarte-Gil","year":"2019","journal-title":"J Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1177\/0961203319886028","article-title":"Predictors of predominant lupus low disease activity state (LLDAS-50)","volume":"28","author":"Babaoglu","year":"2019","journal-title":"Lupus"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1136\/annrheumdis-2016-210571","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sj\u00f6gren's syndrome: A consensus and data-driven methodology involving three international patient cohorts","volume":"76","author":"Shiboski","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209519","article-title":"A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)","volume":"76","author":"van Vollenhoven","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2016.03.002","article-title":"Autoantibodies in sj\u00f6gren's syndrome","volume":"42","author":"Fayyaz","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/7v6qht","article-title":"Sj\u00f6gren's disease and systemic lupus erythematosus overlap syndrome as distinct entity at crossroads of two autoimmune disorders: clinical characterisation from two Italian reference centres for both the diseases","volume":"42","author":"De Marchi","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"501816","DOI":"10.1016\/j.reuma.2025.501816","article-title":"Role of the anti-RO\/SSA antibody in patients with systemic lupus erythematosus","volume":"21","author":"Jim\u00e9nez","year":"2025","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"6728694","DOI":"10.1155\/2019\/6728694","article-title":"TNFAIP3 gene polymorphisms in three common autoimmune diseases: systemic lupus erythematosus, rheumatoid arthritis, and primary sjogren syndrome-association with disease susceptibility and clinical phenotypes in italian patients","volume":"2019","author":"Ciccacci","year":"2019","journal-title":"J Immunol Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2277-x","article-title":"Complement genes contribute sex-biased vulnerability in diverse disorders","volume":"582","author":"Kamitaki","year":"2020","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2009.02.010","article-title":"Latest update on the Ro\/SS-A autoantibody system","volume":"8","author":"Schulte-Pelkum","year":"2009","journal-title":"Autoimmun Rev"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20090585","article-title":"Loss of the lupus autoantigen Ro52\/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway","volume":"206","author":"Espinosa","year":"2009","journal-title":"J Exp Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.06.015","article-title":"RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway","volume":"138","author":"Chiu","year":"2009","journal-title":"Cell"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1779","article-title":"RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate","volume":"10","author":"Ablasser","year":"2009","journal-title":"Nat Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13075-025-03605-9","article-title":"Sicca manifestations and lymphoproliferation in hepatitis C virus: effects of direct acting antiviral therapy on dryness and B-cell activity compared to Sj\u00f6gren's disease","volume":"27","author":"Maher","year":"2025","journal-title":"Arthritis Res Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M003673200","article-title":"La autoantigen is cleaved in the COOH terminus and loses the nuclear localization signal during apoptosis","volume":"275","author":"Ayukawa","year":"2000","journal-title":"J Biol Chem"},{"key":"B27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/08916930400022954","article-title":"Anti-ro\/SSA and la\/SSB antibodies","volume":"38","author":"Franceschini","year":"2005","journal-title":"Autoimmunity"},{"key":"B28","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-12-374994-9.10013-0","article-title":"Origins of Antinuclear Antibodies","volume-title":"Systemic lupus erythematosus","author":"Reeves","year":"2011"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac225","article-title":"Low-dose glucocorticoid withdrawn in systemic lupus erythematosus: a desirable and attainable goal","volume":"62","author":"Ji","year":"2022","journal-title":"Rheumatol (Oxford)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-023-00572-y","article-title":"Comparison of the Effectiveness and Safety of Mycophenolate Mofetil and Cyclophosphamide in Lupus Nephritis: Evidence from a Real-World Study","volume":"10","author":"Zhang","year":"2023","journal-title":"Rheumatol Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1639252\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:25:12Z","timestamp":1759123512000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1639252\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2025.1639252"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1639252","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"article-number":"1639252"}}